Lou Gehrig Center

The Amyotrophic Lateral Sclerosis (ALS), also called Lou Gehrig’s disease, kills motor neurons to weaken muscles. Muscular dystrophy progresses gradually in the four limbs and sometimes, it paralyzes respiratory muscle in the end to lead to death.

The medicine called Rilutek was introduced in the 1990s and has been utilized since then. Rilutek is used with the hope to extend 3 months of life if administered for 2 years. However, many evaluate the medicine brings only less than satisfactory effect on living quality improvement such as muscular recovery. In this situation, a recently-developed cell medicine (Neuronata R Injection) attracts increasing interest as it helps alleviate the disease if utilized in parallel.

Neuronata R Injection was developed as the world’s first stem cell medicine for Lou Gehrig’s disease. Its efficacy to slow or stop the disease progress has been proven. The principle of its mechanism is to utilize nerve protection and anti-inflammation-mediated immuneregulation to help reduce motor neuron destruction and neural inflammatory reaction.